The drug major on Friday (18 December 2020) announced that it has received US drug regulator's approval to market colesevelam hydrochloride tablets, 625 mg.
The drug is a generic equivalent of Welchol tablets of Daiichi Sankyo, Inc. The drug is indicated to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia. It is also indicated to reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH).According to IQVIA, colesevelam hydrochloride tablets had an annual sales of approximately $159 million in the U.S as of September 2020.
Lupin is an innovation-led transnational pharmaceutical company. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets.
On a consolidated basis, the drug major reported a net profit of Rs 211 crore in Q2 FY21 compared with net loss of Rs 127.1 crore in Q2 FY20. Net sales during the quarter declined by 1% year-on-year (YoY) to Rs 3781.80 crore.
Shares of Lupin closed 0.19% higher at Rs 972.20 on Friday.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content